Mutation News and Research

RSS

Whitehead Institute scientists identify novel Parkinson's disease drug target

Using a discovery platform whose components range from yeast cells to human stem cells, Whitehead Institute scientists have identified a novel Parkinson's disease drug target and a compound capable of repairing neurons derived from Parkinson's patients.

25 Oct 2013

New report explains occurrence of breast cancer in women with normal BRCA genes

Since 1994, many thousands of women with breast cancer from families severely affected with the disease have been tested for inherited mutations in BRCA1 and BRCA2. The vast majority of those patients were told that their gene sequences were normal.

25 Oct 2013

Scientists identify link between rare mutations in RINT1 gene and early onset breast cancer risk

An international team of scientists has identified an association between heritable, rare mutations in the RINT1 gene and increased risk of early onset breast cancer, according to research reported today (Oct. 24) at the American Society of Human Genetics 2013 annual meeting in Boston.

25 Oct 2013

Researchers discover novel genetic cause of severe obesity

Researchers from the University of Cambridge have discovered a novel genetic cause of severe obesity which, although relatively rare, demonstrates for the first time that genes can reduce basal metabolic rate - how the body burns calories.

25 Oct 2013

Study uncovers new genetic pathways that could revolutionise acute dendritic leukaemia treatment

Acute dendritic leukaemia is a rare type of leukaemia, but one with the worst prognosis-the average patient survival rate is just 12-14 months-that is difficult to treat. Juan Cruz Cigudosa's team, from the Spanish National Cancer Research Centre's Molecular Cytogenetics Group, has for the first time sequenced the exome -the coding, or protein-generating, regions of the genome- of dendritic cell leukaemia.

24 Oct 2013

A simple blood test may reveal the earliest signs of pancreatic cancer

Reporting on a small preliminary study, Johns Hopkins researchers say a simple blood test based on detection of tiny epigenetic alterations may reveal the earliest signs of pancreatic cancer, a disease that is nearly always fatal because it isn't usually discovered until it has spread to other parts of the body.

23 Oct 2013

Startup Wins Five-Year Exclusive License To Decode Genetics Platform

...

23 Oct 2013

Study identifies new genes involved in autism

A scientific study published on the journal Molecular Psychiatry identifies new genes involved in autism, a polygenic disorder that is difficult to diagnose and treat. Autism spectrum disorders represent a group of neurodevelopmental disorders which affect one out of 80-100 children.

23 Oct 2013

eXtasy software suite quickly and accurately traces origins of genetic disorders

In a bioinformatics breakthrough, iMinds - STADIUS - KU Leuven researchers have successfully applied advanced artificial intelligence to enable the automated analysis of huge amounts of genetic data.

23 Oct 2013

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.

23 Oct 2013

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

23 Oct 2013

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

BRCA1/2 mutations may alter endometrial, ovarian function

Scientists have detected significant differences in endometrial thickness and hormone levels in women with and without BRCA1/2 mutations that may play a role in cancer susceptibility or development.

22 Oct 2013

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.

22 Oct 2013

Study opens doors to novel treatments for aggressive brain cancer

Ludwig researchers have elucidated a key mechanism by which cancer cells change how they metabolize glucose to generate the energy and raw materials required to sustain runaway growth.

22 Oct 2013

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

Einstein researchers receive $2.8M grant to focus on vexing question related to aging and cancer risk

Gene mutations increase as people age, which helps explain why cancer usually strikes older people. But what other consequences of aging promote cancer development or protect against it?

22 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Mutation News and Research

Whitehead Institute scientists identify novel Parkinson's disease drug target

New report explains occurrence of breast cancer in women with normal BRCA genes

Scientists identify link between rare mutations in RINT1 gene and early onset breast cancer risk

Researchers discover novel genetic cause of severe obesity

Study uncovers new genetic pathways that could revolutionise acute dendritic leukaemia treatment

A simple blood test may reveal the earliest signs of pancreatic cancer

Startup Wins Five-Year Exclusive License To Decode Genetics Platform

Study identifies new genes involved in autism

eXtasy software suite quickly and accurately traces origins of genetic disorders

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

BRCA1/2 mutations may alter endometrial, ovarian function

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

Study opens doors to novel treatments for aggressive brain cancer

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Einstein researchers receive $2.8M grant to focus on vexing question related to aging and cancer risk

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

New investigational drug offers potential treatment option for lung cancer

Industry Focus eBook - Cell biology (5th edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News